LBIO 135
Alternative Names: LBIO-135Latest Information Update: 08 Dec 2023
At a glance
- Originator Locanabio
- Class Gene therapies; RNA
- Mechanism of Action Dystrophin expression stimulants; RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy